Apontis Pharma AG Market Cap ($91.63 Million)
Market Cap & Net Worth: Apontis Pharma AG (APPH)
Apontis Pharma AG market cap. Apontis Pharma AG (XETRA:APPH) has a market capitalization of $91.63 Million (€78.38 Million) as of November 2, 2026. Listed on the XETRA stock exchange, this Germany-based company holds position #19347 globally and #1779 in its home market, demonstrating a 2.33% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Apontis Pharma AG's stock price €11.00 by its total outstanding shares 8330000 (8.33 Million). Also see Apontis Pharma AG cash conversion from operations for how efficiently the company converts equity into cash flow.
Apontis Pharma AG Market Cap History (2021–2025)
Apontis Pharma AG market cap history from 2021 to 2025. Data shows change from $194.77 Million to $107.13 Million (-11.14% CAGR). Check current stock price of Apontis Pharma AG for real-time trading data and today's change.
Apontis Pharma AG Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Apontis Pharma AG's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Apontis Pharma AG net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
2.02x
Apontis Pharma AG's market cap is 2.02 times its annual revenue
Latest Price to Earnings (P/E) Ratio
129.88x
Apontis Pharma AG's market cap is 129.88 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $194.77 Million | $51.18 Million | -$745.24K | 3.81x | N/A |
| 2022 | $79.86 Million | $55.73 Million | $2.69 Million | 1.43x | 29.70x |
| 2023 | $46.26 Million | $36.96 Million | -$11.30 Million | 1.25x | N/A |
| 2024 | $97.87 Million | $48.47 Million | $753.57K | 2.02x | 129.88x |
Competitor Companies of APPH by Market Capitalization
Companies near Apontis Pharma AG in the global market cap rankings as of November 2, 2026. Also see Apontis Pharma AG assets under control for a full breakdown of the balance sheet.
Key companies related to Apontis Pharma AG by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #535 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #593 globally with a market cap of $45.23 Billion USD ( CN¥309.13 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #535 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.59 |
| #593 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.23 Billion | CN¥48.46 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.30 |
Market Capitalization of Apontis Pharma AG (2021–2025)
Market capitalization of Apontis Pharma AG from 2021 to today. Between 2021 and today, Apontis Pharma AG's market cap moved from $194.77 Million to $ 107.13 Million, with a yearly change of -11.14%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | €107.13 Million | +9.45% |
| 2024 | €97.87 Million | +111.58% |
| 2023 | €46.26 Million | -42.07% |
| 2022 | €79.86 Million | -59.00% |
| 2021 | €194.77 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 2nd, 2026 the market cap of Apontis Pharma AG was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $91.63 Million USD |
| MoneyControl | $91.63 Million USD |
| MarketWatch | $91.63 Million USD |
| marketcap.company | $91.63 Million USD |
| Reuters | $91.63 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Apontis Pharma AG
Apontis Pharma AG markets and sells medical drugs for indication fields of internal medicine in Germany. It offers single pills and other pharmaceutical products with a focus on cardiovascular diseases, such as hypertension, dylipidemia, secondary prophylaxis, and asthma, as well as respiratory diseases and diabetes. The company was founded in 1946 and is based in Monheim am Rhein, Germany. Apont… Read more